November 20, 2020 6:52 AM
Chinese vaccine maker Sinovac Biotech could have late-stage clinical trial results of its investigational covid-19 vaccine next month, an executive said Friday, November 20, 2020.
CoronaVac is in the final stages of testing in Brazil, Indonesia and Turkey. Preliminary results from early and mid-stage trials this week showed it elicited a rapid immune response but lower antibody levels than seen in people who have recovered from COVID-19.
“Phase III is now working quite well,” Weining Meng, senior manager of Sinovac, told an online conference. “I guess next month we might have some data available.”
The findings follow news from Pfizer Inc, BioNTech and Moderna, as well as from Russia this month, about investigational vaccines that have shown greater than 90% efficacy, based on interim data from large-scale trials and advanced stage.
Brazil and Indonesia are considering CoronaVac for vaccines in the coming months.
Meng said the company’s manufacturing agreements with local partners, including PT Bio Farma in Indonesia, will help Sinovac lower production costs and speed up delivery once its vaccine gets regulatory approval.
Was this news helpful to you ?: